Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia

Promoter Methylation in MLL-Rearranged Childhood AML

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01229956

Enrollment

Registered

2010-10-28

Start date

2010-11-30

Completion date

Unknown

Last updated

2016-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

childhood acute myeloid leukemia in remission, recurrent childhood acute myeloid leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies

Brief summary

RATIONALE: Studying samples of tissue from patients with cancer the in laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in tissue samples from young patients with acute myeloid leukemia.

Detailed description

OBJECTIVES: * To determine whether the pattern of global and TSG-specific promoter CpG island hypermethylation and gene silencing that we have shown characterizes MLL-rearranged (MLL-r) infant bilineage ALL is also characteristic of other subsets of MLL-r leukemia. OUTLINE: Previously collected cryopreserved cells from diagnosis are analyzed for promoter methylation via HELP arrays, gene expression arrays, and RT-qPCR. PROJECTED ACCRUAL: A total of 32 samples (8 from each of 4 biologically defined cohorts) will be analyzed.

Interventions

GENETICDNA methylation analysis

GENETICgene expression analysis

GENETICmicroarray analysis

GENETICreverse transcriptase-polymerase chain reaction

OTHERlaboratory biomarker analysis

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 18 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Available cryopreserved cells from diagnosis * At least 2 x 10\^7 viably cryopreserved cells * One of the following biologically defined cytogenetics/molecular cohorts: * t(9;11) * t(11;19) * Other 11q23 translocations * Normal cytogenetics PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Identification of differential patterns of promoter hypermethylation and gene expression in pairwise comparisons with other cohorts and normal controls	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026